natgillin/translations-raw huggingface dataset:
The use of Protopy ointment in patients with genetic epidermal barrier defects such as Netherton’s syndrome is not recommended due to the potential for permanently increased systemic absorption of tacrolimus.
Mazila Protopy ni priporočljivo uporabljati pri bolnikih z genetskimi okvarami epidermalne pregrade, npr. pri bolnikih z Nethertonovim sindromom, ker obstaja možnost trajno zvečane sistemske absorpcije takrolimusa.
The use of Quadrisol is not permitted in horses producing milk that is intended for human consumption.
Zdravila Quadrisol ni dovoljeno uporabljati pri konjih, ki proizvajajo mleko za prehrano ljudi.
The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and cholesterol), and urinary tract infections.
Uporaba zdravila Rapamune sočasno z zaviralci kalcinevrina in kortikosteroidi je bila povezana z zvečanim tveganjem poslabšanja ledvične funkcije, nenormalnimi izvidi serumskih lipidov (vključno z zvišanimi trigliceridi in holesterolom) in okužbami sečil.
The use of Rapamune in combination with calcineurin inhibitors and corticosteroids was associated with an increased risk of deterioration of renal function, serum lipid abnormalities (including, but not limited to, increased serum triglycerides and total cholesterol), and urinary tract infections (see section 4.8).
Uporaba zdravila Rapamune sočasno z zaviralci kalcinevrina in kortikosteroidi je bila povezana z zvečanim tveganjem poslabšanja ledvične funkcije, nenormalnimi izvidi serumskih lipidov (vključno z zvišanimi trigliceridi in holesterolom) in okužbami sečil (glejte poglavje 4.8).
The use of Rapamune in renal transplant patients was associated with increased serum cholesterol and triglycerides that may require treatment.
Uporaba zdravila Rapamune po presaditvi ledvice je bila povezana z zvišanjem serumskega holesterola in trigliceridov, ki lahko zahteva zdravljenje.
The use of Rapamune is not recommended in this population.
Uporaba zdravila Rapamune v tej skupini ni priporočljiva.
The use of Rapamune may lead to increased levels of cholesterol and triglycerides (blood fats) in your blood that may require treatment.
Uporaba zdravila Rapamune lahko povzroči zvišano raven holesterola in trigliceridov (krvnih maščob) v krvi, ki jo bo morda treba zdraviti.
The use of Raptiva is not expected to affect your ability to drive and use machines.
Ni pričakovati, da bi uporaba zdravila Raptiva vplivala na vašo sposobnost upravljanja vozil in strojev.
The use of Rasitrio in children and adolescents up to 18 years of age is not recommended.
Uporaba zdravila Rasitrio pri otrocih in mladostnikih do 18. leta starosti ni priporočena.
The use of RAVICTI in women of childbearing potential must be accompanied by the use of effective contraception (see section 4.4).
Zdravilo RAVICTI je treba pri ženskah v rodni dobi uporabljati sočasno z učinkovito kontracepcijo (glejte poglavje 4.4).
The use of Rebif is not recommended if you are breast-feeding.
V obdobju dojenja uporaba zdravila Rebif ni priporočljiva.
The use of Renvela powder for oral suspension in patients with a history of difficulty swallowing should be considered.
Pri bolnikih z anamnezo težav s požiranjem razmislite o uporabi praška za peroralno suspenzijo Renvela.
The use of REYATAZ in children less than 3 months of age and weighing less than 5 kg has not been studied due to the risk of serious complications.
Uporabe zdravila REYATAZ pri otrocih, mlajših od 3 mesecev in s telesno maso, manjšo od 5 kg, zaradi tveganja za pojav resnih zapletov niso raziskovali.
The use of Rheumocam oral suspension for dogs may be considered for an even more precise dosing.
Za še natančnejše odmerjanje presodimo o uporabi peroralne suspenzije za pse Rheumocam.
The use of Ribavirin and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).
Uporaba ribavirina in interferona alfa-2b ali peginterferona alfa-2b pri otrocih in mladostnikih , ki imajo ali so kdaj imeli hude psihiatrične motnje v sedanji ali pretekli anamnezi je kontraindicirana (glejte poglavje 4.3).
The use of Ribavirin and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).
Uporaba ribavirina in interferona alfa-2b ali peginterferona alfa-2b pri otrocih in mladostnikih z obstoječimi hudimi psihiatričnimi motnjami ali s hudimi psihiatričnimi motnjami v anamnezi je kontraindicirana (glejte poglavje 4.3).
The use of Ribavirin BioPartners tablets is not recommended.
Uporaba zdravila Ribavirin BioPartners tablet ni priporočljiva.
The use of ribavirin in combination treatment with peginterferon alfa-2b or interferon alfa-2b was evaluated in a number of clinical trials.
Uporabo ribavirina v kombinirani terapiji s peginterferonom alfa-2b ali interferonom alfa-2b so ovrednotili v številnih kliničnih preskušanjih.
The use of ribavirin is contraindicated in patients with severe hepatic impairment or decompensated cirrhosis (see section 4.3).
Uporaba ribavirina je kontraindicirana pri bolnikih s hudo jetrno okvaro ali dekompenzirano cirozo (glejte poglavje 4.3).
The use of Ribavirin Teva Pharma B.V. and interferon alfa-2b or peginterferon alfa-2b in children and adolescents with existence of or history of severe psychiatric conditions is contraindicated (see section 4.3).
Uporaba zdravila Ribavirin Teva Pharma B.V. in interferona alfa-2b ali peginterferona alfa-2b pri otrocih in mladostnikih z obstoječimi hudimi psihiatričnimi motnjami ali s hudimi psihijatričnimi motnjami v anamnezi je kontraindicirana (glejte poglavje 4.3).
The use of Ribavirin Teva Pharma B.V. is contraindicated during pregnancy.
Uporaba zdravila Ribavirin Teva Phama B.V. je kontraindicirana v času nosečnosti.
The use of Ribavirin Teva Pharma B.V. is not recommended
Uporaba zdravila Ribavirin Teva Pharma B.V. ni priporočena.
The use of rifampicin with
Uporaba rifampicina skupaj z indinavirjem je kontraindicirana.
The use of Riprazo in children and adolescents up to 18 years of age is not recommended.
Uporaba zdravila Riprazo pri otrocih in mladostnikih, ki so stari manj kot 18 let, ni priporočena.
The use of ritonavir may be considered in pregnancy only when the benefits outweigh the risk to the foetus.
Uporaba ritonavirja pride med nosečnostjo v poštev le, če koristi odtehtajo tveganje za plod.
The use of rivaroxaban is not
Uporaba rivaroksabana
The use of rivastigmine in patients with severe dementia of Alzheimer's disease or associated with Parkinson's disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended.
Uporabe rivastigmina pri bolnikih s hudo Alzheimerjevo demenco ali demenco, povezano s Parkinsonovo boleznijo, drugimi vrstami demence ali drugimi vrstami okvar spomina (npr. z zmanjšanjem kognitivnih funkcij, povezanim s starostjo) niso raziskovali, zato uporaba pri teh populacijah bolnikov ni priporočena.
The use of rivastigmine in patients with severe dementia of Alzheimer’s disease or associated with Parkinson’s disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended.
Uporabe rivastigmina pri bolnikih s hudo demenco in Alzheimerjevo boleznijo ali z demenco, povezano s Parkinsonovo boleznijo, z drugimi vrstami demence ali drugimi vrstami spominskih okvar (npr. starostnega kognitivnega upada) niso raziskali, zato ni priporočena.
The use of rivastigmine in patients with severe dementia of Alzheimer’s disease or associated with Parkinson’s disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended.
Uporabe rivastigmina pri bolnikih s težko demenco pri Alzheimerjevi bolezni ali v povezavi s Parkinsonovo boleznijo, z drugimi vrstami demence ali drugimi vrstami spominskih okvar (na primer starostnega kognitivnega upada) niso raziskali, zato uporaba pri teh skupinah bolnikov ni priporočena.
The use of rivastigmine in patients with severe dementia of Alzheimer’s disease or associated with Parkinson’s disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended.
Uporabe rivastigmina pri bolnikih s težko demenco pri Alzheimerjevi bolezni, težko demenco, povezano s Parkinsonovo boleznijo, z drugimi vrstami demence ali drugimi vrstami spominskih okvar (na primer starostnega kognitivnega upada) niso raziskali, zato uporaba pri teh skupinah bolnikov ni priporočena.
The use of salicylates (for example, acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever) should be avoided for 6 weeks following vaccination with ProQuad.
6 tednov po cepljenju s cepivom ProQuad se je treba izogibati jemanju salicilatov (npr. acetilsalicilne kisline, ki jo vsebujejo mnoga zdravila proti bolečinam in vročini).
The use of Sevelamer carbonate Zentiva powder for oral suspension in patients with a history of difficulty swallowing should be considered.
Pri bolnikih z anamnezo težav s požiranjem je potrebno razmisliti o uporabi praška za peroralno suspenzijo Sevelamer carbonate Zentiva.
The use of several vials may be necessary to obtain the quantity of rasburicase required for one administration.
Morda boste morali uporabiti več vial, da bi dobili količino razburikaze, potrebno za en odmerek.
The use of sevoflurane in humans increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Pri ljudeh uporaba sevoflurana zveča tako intenzivnost kot trajanje živčnomišične blokade, inducirane z nedepolarizirajočimi mišičnimi relaksanti.
The use of Silgard in adult women should take into consideration the variability of HPV type prevalence in different geographical areas.
Pri uporabi cepiva Silgard pri odraslih ženskah je treba upoštevati variabilnost v razširjenosti tipa HPV na različnih geografskih področjih.
The use of silodosin in patients with severe renal impairment (CLCR <30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba silodozina pri bolnikih s hudo okvaro delovanja ledvic (CLCR <30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of silodosin in patients with severe renal impairment (CLCR <30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba zdravila Silodyx pri bolnikih s hudo okvaro delovanja ledvic (CLCR <30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of silodosin in patients with severe renal impairment (CLCR <30 ml/min) is not recommended (see sections 4.2 and 5.2).
Uporaba zdravila Urorec pri bolnikih s hudo okvaro delovanja ledvic (CLCR <30 ml/min) ni priporočljiva (glejte poglavji 4.2 in 5.2).
The use of single-agent crizotinib in the treatment of ALK-positive advanced NSCLC was investigated in 2 multinational, single-arm studies (Studies 1001 and 1005).
Samostojno uporabo krizotiniba pri zdravljenju ALK-pozitivnega napredovalega NSCLC so raziskovali v 2 mednarodnih študijah z eno skupino bolnikov (Študiji 1001 in 1005).
The use of SIRTURO for longer than 6 months has not been studied in clinical trials.
V kliničnih študijah niso raziskali uporabe zdravila SIRTURO, ki bi trajala dlje kot 6 mesecev.
The use of some anaesthetic regimens that include sevoflurane may result in bradycardia that is reversible with anticholinergics.
Uporaba nekaterih anestezijskih shem, ki vključujejo sevofluran, lahko povzroči bradikardijo, ki je reverzibilna z antiholinergiki.
The use of St. John’s Wort should be avoided with Lojuxta.
Uporabi šentjanževke v kombinaciji z zdravilom Lojuxta se je treba izogibati.
The use of Stribild in children and adolescents has not yet been studied.
Uporabe zdravila Stribild pri otrocih in mladostnikih še niso preučili.
The use of Stribild must be accompanied by the use of effective contraception (see section 4.5).
Pri uporabi zdravila Stribild je treba uporabljati učinkovito kontracepcijo (glejte poglavje 4.5).
The use of supplementary supportive treatments improves prognosis.
Tekočinska terapija in ostale podporne terapije so potrebne za izboljšanje prognoze.
The use of tacrolimus ointment is not recommended in patients with a skin barrier defect, such as Netherton’s syndrome, lamellar ichthyosis, generalized erythroderma or cutaneous Graft Versus Host Disease.
Mazila s takrolimusom ni priporočljivo uporabljati pri bolnikih z okvaro kožne pregrade, npr. pri bolnikih z Nethertonovim sindromom, lamelarno ihtiozo, generalizirano eritrodermijo, ali kožnimi manifestacijami reakcije presadka proti gostitelju.
The use of Telmisartan Actavis in children and adolescents up to the age of 18 years is not recommended.
Uporaba zdravila Telmisartan Actavis pri otrocih in mladostnikih do 18 leta starosti ni priporočljiva.
The use of telmisartan in combination with aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see section 4.3).
Uporaba kombinacije telmisartana in aliskirena je kontraindicirana pri bolnikih s sladkorno boleznijo ali ledvično okvaro (GFR < 60 ml/min/1,73 m2) (glejte poglavje 4.3).
The use of Telmisartan Teva in children and adolescents up to the age of 18 years is not recommended.
Zdravilo Telmisartan Teva se ne priporoča otrokom in mladostnikom, mlajšim od 18 let.
The use of tenofovir disoproxil fumarate is not recommended in paediatric patients with renal impairment (see section 4.2).
Uporaba dizoproksiltenofovirijevega fumarata pri pediatričnih bolnikih z ledvično okvaro ni priporočljiva (glejte poglavje 4.2).
The use of tenofovir disoproxil fumarate is not recommended in paediatric patients with renal impairment (see section 4.4).
Uporaba dizoproksiltenofovirijevega fumarata pri pediatričnih bolnikih z ledvično okvaro ni priporočljiva (glejte poglavje 4.4).
The use of tenofovir disoproxil fumarate is not recommended in paediatric patients with renal impairment (see sections 4.2 and 4.4).
Uporaba dizoproksiltenofovirijevega fumarata pri pediatričnih bolnikih z ledvično okvaro ni priporočljiva (glejte poglavji 4.2 in 4.4).
The use of tenofovir disoproxil fumarate may be considered during pregnancy, if necessary.
Če je potrebno, se lahko pretehta možnost uporabe dizoproksiltenofovirijevega fumarata med nosečnostjo.
The use of the following medicines, together with Agenerase, should only take place on the basis of medical advice: anaesthetics (e.g. lidocaine), antibiotics (e.g. rifabutin, clarithromycin, dapsone and erythromycin), antifungals (e.g. ketoconazole, itraconazole), antimalarials (e.g. halofantrine), anticonvulsant medicines (e.g. carbamazepine, phenytoin and phenobarbital), calcium channel blockers (e.g. amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine and verapamil), cholesterol lowering medicines (e.g. atorvastatin, lovastatin and simvastatin), erectile dysfunction medicines (e.g. sildenafil and vardenafil), non-nucleoside reverse transcriptase inhibitors (e.g. delavirdine, efavirenz and nevirapine), opioids (e.g. methadone), hormones like oestrogens and progestogens (e.g. hormonal contraceptives such as the ‘pill’), some glucocorticoids (e.g. fluticasone propionate and budesonide), tricyclic antidepressants (e.g. desipramine and nortriptyline), sedative agents (e.g. midazolam administered by injection), paroxetine, and others (e.g. clozapine and loratadine).
Naslednja zdravila se smejo uporabljati sočasno z zdravilom Agenerase le, če tako odredi zdravnik: anestetiki (npr. lidokain), antibiotiki (npr. rifabutin, klaritromicin, dapson in eritromicin), antimikotiki (npr. ketokonazol, itrakonazol), antimalariki (npr. halofantrin), antiepileptiki (npr. karbamazepin, fenitoin in fenobarbital), zaviralci kalcijevih kanalčkov (npr. amlodipin, diltiazem, felodipin, isradipin, nikardipin, nifedipin, nimodipin, nisoldipin in verapamil), zdravila za zniževanje holesterola (npr. atorvastatin, lovastatin in simvastatin), zdravila proti motnjam erekcije (npr. sildenafil in vardenafil), nenukleozidni zaviralci reverzne transkriptaze (npr. delavirdin, efavirenz in nevirapin), opioidi (npr. metadon), hormoni kot so estrogeni in progestogeni (npr. hormonski kontraceptivi kot so kontracepcijske tabletke), nekateri glukokortikoidi (npr. flutikazonpropionat in budezonid), triciklični antidepresivi (npr. dezipramin in nortriptilin), pomirjevala (npr. midazolam v obliki injekcije), paroksetin in druga (klozapin in loratadin).
The use of the following medicines, together with Agenerase, should only take place on the basis of medical advice: anaesthetics (e.g. lidocaine), antibiotics (e.g. rifabutin, clarithromycin, dapsone and erythromycin), antifungals (e.g. ketoconazole, itraconazole), antimalarials (e.g. halofantrine), anticonvulsant medicines (e.g. carbamazepine, phenytoin and phenobarbital), calcium channel blockers (e.g. amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine and verapamil), cholesterol lowering medicines (e.g. atorvastatin, lovastatin and simvastatin), erectile dysfunction medicines (e.g. sildenafil and vardenafil), non-nucleoside reverse transcriptase inhibitors (e.g. delavirdine, efavirenz and nevirapine), opioids (e.g. methadone), hormones like oestrogens and progestogens (e.g. hormonal contraceptives such as the ‘pill’), some glucocorticoids (e.g. fluticasone propionate and budesonide), tricyclic antidepressants (i.e. desipramine and nortriptyline), sedative agents (e.g. midazolam administered by injection), paroxetine, and others (e.g. clozapine and loratadine).
Naslednja zdravila se smejo uporabljati sočasno z zdravilom Agenerase le, če tako odredi zdravnik: anestetiki (npr. lidokain), antibiotiki (npr. rifabutin, klaritromicin, dapson in eritromicin), antimikotiki (npr. ketokonazol, itrakonazol), antimalariki (npr. halofantrin), antiepileptiki (npr. karbamazepin, fenitoin in fenobarbital), zaviralci kalcijevih kanalčkov (npr. amlodipin, diltiazem, felodipin, isradipin, nikardipin, nifedipin, nimodipin, nisoldipin in verapamil), zdravila za zniževanje holesterola (npr. atorvastatin, lovastatin in simvastatin), zdravila proti motnjam erekcije (npr. sildenafil in vardenafil), nenukleozidni zaviralci reverzne transkriptaze (npr. delavirdin, efavirenz in nevirapin), opioidi (npr. metadon), hormoni kot so estrogeni in progestogeni (npr. hormonski kontraceptivi kot so kontracepcijske tabletke), nekateri glukokortikoidi (npr. flutikazonpropionat in budezonid), triciklični antidepresivi (npr. dezipramin in nortriptilin), benzodiazepini (npr. midazolam, triazolam), paroksetin in druga (klozapin in loratadin).
The use of the following medicines, together with Agenerase, should only take place on the basis of medical advice: anaesthetics (e.g. lidocaine), antibiotics (e.g. rifabutin, clarithromycin, dapsone and erythromycin), antifungals (e.g. ketoconazole, itraconazole), antimalarials (e.g. halofantrine), anticonvulsant medicines (e.g. carbamazepine, phenytoin and phenobarbital), calcium channel blockers (e.g. amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine and verapamil), cholesterol lowering medicines (e.g. atorvastatin, lovastatin and simvastatin), erectile dysfunction medicines (e.g. sildenafil and vardenafil), non-nucleoside reverse transcriptase inhibitors (e.g. delavirdine, efavirenz and nevirapine), opioids (e.g. methadone), hormones like oestrogens and progestogens (e.g. hormonal contraceptives such as the ‘pill’), some glucocorticoids (e.g. fluticasone propionate and budesonide), tricyclic antidepressants (i.e. desipramine and nortriptyline), sedative agents (e.g. midazolam administered by injection), paroxetine, and others (e.g. clozapine and loratadine).
Naslednja zdravila se smejo uporabljati sočasno z zdravilom Agenerase le, če tako odredi zdravnik: anestetiki (npr. lidokain), antibiotiki (npr. rifabutin, klaritromicin, dapson in eritromicin), antimikotiki (npr. ketokonazol, itrakonazol), antimalariki (npr. halofantrin), antiepileptiki (npr. karbamazepin, fenitoin in fenobarbital), zaviralci kalcijevih kanalčkov (npr. amlodipin, diltiazem, felodipin, isradipin, nikardipin, nifedipin, nimodipin, nisoldipin in verapamil), zdravila za zniževanje holesterola (npr. atorvastatin, lovastatin in simvastatin), zdravila proti motnjam erekcije (npr. sildenafil in vardenafil), nenukleozidni zaviralci reverzne transkriptaze (npr. delavirdin, efavirenz in nevirapin), opioidi (npr. metadon), hormoni kot so estrogeni in progestogeni (npr. hormonski kontraceptivi kot so kontracepcijske tabletke), nekateri glukokortikoidi (npr. flutikazonpropionat in budezonid), triciklični antidepresivi (npr. dezipramin in nortriptilin), pomirjevala (npr. midazolam v obliki injekcije), paroksetin in druga (klozapin in loratadin).
The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see also sections 4 and 8).
Uporaba zdravila mora istočasno temeljiti na potrjenih ocenah mešanih okužb (ali tveganje za okužbe, kjer se uporablja preventiva) (glejte poglavje 4 in 8).
The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see also sections 4.2 and 4.9).
Uporaba zdravila mora istočasno temeljiti na potrjenih ocenah mešanih okužb (ali tveganje za okužbe, kjer se uporablja preventiva) (glejte poglavje 4.2 in 4.9).
The use of the product should be based on the confirmed diagnosis of mixed infection (or risk of infection, where prevention applies) at the same time (see also sections 4.2 and 4.9).
Uporaba zdravila mora istočasno temeljiti na potrjenih ocenah mešanih okužb (ali tveganje za okužbe, kjer se uporablja preventiva). (glejte poglavje 4.2 in 4.9).
The use of the vaccine should be based on official recommendations.
Uporabljati se mora v skladu z uradnimi priporočili.
The use of the veterinary medicinal product in dogs of less than 10 kg or more than 40 kg bodyweight, therefore, should be subject to a risk/benefit assessment performed by the veterinarian.
Pri uporabi zdravila pri psih s telesno težo, manjšo od 10 kg ali večjo od 40 kg, je zato potrebna ocena razmerja med tveganjem in koristjo, ki jo opravi veterinar.
The use of the veterinary medicinal product in pre-pubertal dogs has not been investigated.
Uporabe tega zdravila za uporabo v veterinarski medicini pri psih pred puberteto niso raziskali.
The use of the veterinary medicinal product in pre-pubertal ferrets has not been investigated.
Uporaba zdravila za uporabo v veterinarski medicini pri belih dihurjih pred puberteto ni bila raziskana.
The use of the veterinary medicinal product in pregnant and lactating bitches or in dogs intended for breeding should be based on a benefit/risk assessment by the responsible veterinarian.
Uporaba zdravila za uporabo v veterinarski medicini pri brejih psicah ali psicah v laktaciji naj bo le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
The use of the veterinary medicinal product in pregnant and lactating cats should therefore be based on a benefit-risk assessment by the responsible veterinarian.
Uporaba zdravila za uporabo v veterinarski medicini pri brejih mačkah ali mačkah v laktaciji naj bo le v skladu z oceno razmerja korist-tveganje odgovornega veterinarja.
The use of the veterinary medicinal product in pregnant and lactating cats should therefore be based on a benefit-risk assessment by the responsible veterinarian.
Uporaba zdravila za uporabo v veterinarski medicini pri brejih mačkah ali mačkah v laktaciji naj bo le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.